UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest
event reported): SEPTEMBER 22, 2008
ISOLAGEN, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
DELAWARE
|
|
001-31564
|
|
87-0458888
|
|
(State or other Jurisdiction of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
|
|
|
405 EAGLEVIEW BLVD., EXTON,
PA
|
|
19341
|
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrant’s telephone number,
including area code:
(484) 713-6000
|
|
NOT
APPLICABLE
|
|
(Former name or former address if changed since last report.)
|
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
1
Item 1.01 Entry into a
Material Definitive Agreement
See Item 8.01 the contents of
which are incorporated herein by reference.
Item 8.01 Other Events
On September 2 5, 2008, Isolagen,
Inc., a Delaware corporation (the “Company”), issued a press
release announcing that it has reached an agreement in principle to settle its
securities class action lawsuit and its two derivative actions against the
Company and certain of its current and former officers and directors (Civil
Action Case No. 05-cv-04983-RB, Case No. 06-cv-01302-RB and Case
No. 08-cv-724-RB).
A copy of the press release is
attached as Exhibit 99.1 hereto, the contents of which are incorporated
herein by reference.
In connection with the agreement in
principle discussed above, the Company entered into a Release Agreement with
Frank L. DeLape, Michael Macaluso, Michael Avignon, Robert J. Bitterman, Olga
Marko, Martin E. Schmieg, William K. Boss, Jr., Steven Morrell, Henry Y.L. Toh,
Ralph V. DeMartino, Susan Ciallella, and Marshall G. Webb (the
“Individual Defendants”) containing a release from the Company to
the Individual Defendants from all claims that the Company could have asserted
that arise out of, or are based upon: (1) the claims or allegations
asserted by current or former holders of Company securities in the securities
class action lawsuit and in the two derivative actions; and (2) services
rendered and actions taken in connection with defending, managing, and settling
the securities class action lawsuit and in the two derivative actions.
Item 9.01 Financial
Statement and Exhibits.
(a) Not applicable.
(b) Not applicable.
(c) Not applicable.
(d) Exhibits.
|
|
99.1
|
|
Press release dated September 25,
2008
|
SIGNATURE
Pursuant to the
requirements of the Securities and Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
ISOLAGEN,
INC.
Date: September 25, 2008
By:
/
s/ Todd J.
Greenspan
Todd J. Greenspan,
Chief Financial Officer
2